Almost half of Maine’s medical cannabis products would fail the contaminant tests that the state’s recreational cannabis products are subjected to. That’s the conclusion of a study conducted by Maine’s own Office of Cannabis Policy (OCP).
In an email letter sent last week – seen by Analytical Cannabis – the Department of Cannabis Control (DCC) reminded licensed labs that they are “required to accurately report testing results for cannabis batches.”
The researchers say their findings add to the growing body of evidence that psilocybin can be used in a clinical setting to treat depression.
Cannabis consumers have higher levels of cadmium and lead in their blood than people who don’t consume the drug, according to a new study.
The US Department of Health and Human Services (HHS) has recommended that cannabis be reclassified from Schedule I to the less restrictive Schedule III within the Controlled Substance Act.
A significant minority of medical cannabis patients go on to develop cannabis use disorder (CUD), according to a new study. This proportion, however, is still lower than the proportion of recreational consumers with CUD.
Cannabis products in Oregon no longer have to be tested for Aspergillus fungi following a suspension order from the Oregon Court of Appeals.
State regulators in Colorado have issued another health and safety notice after “potentially unsafe levels” of total yeast and mold was found in a batch of cannabis flower.
Cannabis and hallucinogens are more popular than ever in the US, according to an ongoing National Institutes of Health (NIH) survey.
Ohioans will have the chance to legalize recreational, adult-use cannabis on November 7 this year.